RNAi: antifungal therapy against Invasive pulmonary aspergillosis (IPA) in humans

Noncoding RNAs, known as miRNAs, regulate gene expression. Most miRNAs are converted from DNA sequences into primary miRNAs, processed into precursors, and matured. Survival or virulence of species is targeted by RNAi antifungal treatment. Silencing these genes can reduce fungal proliferation and pathogenicity, thereby improving therapy. RNAi can be used to treat ; however, most research has been conducted in controlled laboratory or animal studies. The immune system neutralizes spores, so not everyone gets sick. Aspergillosis can range from moderate allergic reactions to invasive, life-threatening disease. MiRNAs have been studied in numerous diseases, but their role in immune responses to pulmonary and systemic fungal infections is still being discovered. During disease progression, fungal pathogens can alter signaling and expression of miRNAs in the genetic network. Future investigations on the biological purpose of miRNAs, previously assumed to be a consequence of miRNA synthesis, will illuminate the regulatory function of the miRNA network in plant innate immunity. MiRNAs and their intended targets present opportunities for novel pathogen-fighting strategies and technologies.